Fans' vote sends emphatic message on Bloom's investment at Hearts
It was announced earlier this month that the Albion chairman intended to plough £9.86million into the Edinburgh club in return for a 29% stake in the Jambos via non-voting shares.
Bloom would also be entitled to one seat on the board, although he is expected to appoint someone on his behalf.
The transaction had to be approved by members of Foundation of Hearts, the supporters' group who count as the club's majority shareholder, with a simple majority of more than 50 per cent of votes cast required in order to confirm the deal goes ahead.
Following a consultation period that ran until Monday, the FoH announced that 98.5% have given the green light for Bloom to come on board.
By happy coincidence, the news comes with Union St Gillosie, the Belgian club in which Bloom has a minority stake, still celebrating winning the title for the first time in 90 years.
Verbruggen targets more progress for next season - including penalties
How Hurzeler's points tally measures up - and is it a fair comparison?
'Foundation members have voted to accept the proposed investment in the club by Tony Bloom,' read a statement on Monday evening. 'A total of 6208 votes were cast, with 6112 voting in favour and 96 voting against. In percentage terms, this resulted in 98.5% voting in favour of the proposal.'
An extraordinary general meeting of the club's shareholders will now be called in order to formally approve a transaction which Foundation of Hearts chairman Gerry Mallon said at the start of the consultation period could 'really help shake up the Scottish football establishment'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Is MicroStrategy Stock a Buy, Sell, or Hold for July 2025?
Despite all the noise of trade tensions, recession warnings, and geopolitical flare-ups, a second Donald Trump presidency has certainly been a boon for the crypto market this year. Trump's tone has shifted increasingly in favor of crypto, with bold ideas like establishing a U.S. strategic crypto reserve gaining traction. At the same time, major players like BlackRock (BLK) and Fidelity (FNF) have also stepped in with Bitcoin (BTCUSD) exchange-traded funds (ETFs), making it easier for both institutions and everyday investors to gain exposure. In fact, Bitcoin's rally has been nothing short of explosive this year, soaring past the $100,000 mark and hitting a stunning $111,946 high in May. At the center of this crypto storm is MicroStrategy, now rebranded as Strategy (MSTR), which has doubled down with laser focus. Is Palantir Stock a Buy, Sell, or Hold for July 2025? Is Archer Aviation Stock a Buy, Sell, or Hold for July 2025? Oklo Just Announced a New Nuclear Fuel Deal. Is OKLO Stock a Buy Here? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. The company's founder and Executive Chairman, Michael Saylor, continues to lean in with bold conviction. Speaking at a Bitcoin conference in Prague last month, Saylor projected that Bitcoin could reach an astounding $21 million per coin in the next 21 years. That certainly explains the company's relentless buying spree. So, with Strategy riding high on Bitcoin's momentum, is MSTR stock a buy, sell, or hold in July? Strategy has firmly established itself as the first public company to adopt Bitcoin as its primary treasury asset, effectively transforming its business model into a leveraged bet on the crypto. Through a mix of equity offerings, debt issuance, and operational cash flow, the company has aggressively accumulated Bitcoin, positioning itself as a high-risk, high-reward vehicle for investors seeking indirect exposure to the crypto market. Fueled by the crypto's explosive rise and the company's aggressive accumulation strategy, MSTR stock has become a hot trade this year. With a market capitalization hovering around $110 billion, shares have surged 29% year-to-date (YTD), crushing the broader S&P 500 Index's ($SPX) 5.4% return in 2025. Zoom out, and the rally looks even more striking. Over the past 52 weeks, MSTR stock has soared an eye-popping 173%, leaving the broader market's modest 13% gain in the dust. Strategy's fiscal 2025 first-quarter earnings, released on May 1, offered a mixed bag for investors. Revenue came in at $111.1 million, marking a 3.6% year-over-year (YOY) decline and falling short of analyst forecasts. But the bigger concern was the sharp swing in profitability. The company's net loss ballooned to $16.49 per share, a steep drop from just $0.31 per share in the same quarter last year. Amid the top-line miss and widening losses, one standout bright spot was Strategy's Subscription Services segment, which posted a remarkable 61.6% YOY jump to $37.1 million. On the liquidity side, Strategy also showed improvement, closing the quarter with $60.3 million in cash and cash equivalents, up from $38.1 million at the end of 2024. That offers the company some cushion as it continues to pursue its bold crypto-centric strategy. Strategy is riding high on Bitcoin's surge, having already locked in $5.8 billion in gains, achieving 58% of its full-year target in just the first leg of 2025. Riding that wave of momentum, the company isn't holding back. It has raised its Bitcoin yield goal for the year from 15% to 25% and bumped its dollar gain target from $10 billion to an ambitious $15 billion, signaling an even more aggressive stance as it leans further into its crypto-first strategy. The company is showing no signs of slowing down its Bitcoin buying spree. In its latest move, Strategy scooped up another 4,980 BTC, according to a recent filing with the U.S. Securities and Exchange Commission. This fresh addition pushes its total stash to a staggering 597,325 coins, worth more than $63 billion. The relentless accumulation further cements Strategy's position as the undisputed heavyweight among corporate Bitcoin holders, doubling down on its high-stakes bet as Bitcoin prices continue to climb. Overall, Wall Street isn't backing down from its bullish view on Strategy, with the consensus firmly tilted toward a 'Strong Buy" rating. Of the 13 analysts offering recommendations, 11 advocate for a solid 'Strong Buy" rating, one suggests a 'Moderate Buy,' and the remaining analyst gives a 'Strong Sell" rating. The average analyst price target of $534.77 indicates 43% potential upside from current price levels. Meanwhile, the Street-high target of $650 suggests MSTR stock can rally as much as 74% from here. With Bitcoin on a tear and Strategy staying aggressive in its accumulation, MSTR has emerged as a key proxy for crypto market momentum. For investors seeking amplified exposure to Bitcoin's upside, Strategy offers a bold, high-risk gateway to BTC's explosive potential. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Asian Penny Stocks To Watch In July 2025
As global markets celebrate positive developments, such as the U.S. and China signing a new trade deal, Asian indices have also shown resilience and potential for growth. Penny stocks may be an older term, but they continue to represent intriguing opportunities in the investment landscape, particularly within smaller or newer companies. By identifying those with strong financial health and clear growth prospects, investors can uncover potential gems that offer both stability and upside in today's market conditions. Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.29 HK$813.93M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$2.04 HK$3.53B ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.27 HK$1.89B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.435 SGD176.3M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.05 HK$1.75B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.25 SGD8.86B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.182 SGD36.26M ★★★★★★ BRC Asia (SGX:BEC) SGD3.12 SGD855.97M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.64 HK$53.16B ★★★★★★ United Energy Group (SEHK:467) HK$0.52 HK$13.44B ★★★★★★ Click here to see the full list of 1,001 stocks from our Asian Penny Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: HuBei NengTer Technology Co., Ltd operates an ecommerce platform focused on the supply chain of plastic raw materials in China, with a market cap of CN¥8.82 billion. Operations: Currently, there are no reported revenue segments available for this company. Market Cap: CN¥8.82B HuBei NengTer Technology Ltd., with a market cap of CN¥8.82 billion, recently reported first-quarter sales of CN¥2,877.27 million and net income of CN¥215.9 million, reflecting an improvement from the previous year's figures despite a decline in sales compared to last year. The company has completed a share buyback worth CN¥329.98 million, enhancing shareholder value without significant dilution over the past year. While unprofitable with increasing losses over five years, it maintains sufficient cash runway for more than three years and holds more cash than its total debt, indicating financial stability amidst volatility concerns. Unlock comprehensive insights into our analysis of HuBei NengTer TechnologyLtd stock in this financial health report. Examine HuBei NengTer TechnologyLtd's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥11.99 billion. Operations: No specific revenue segments are reported for Tianjin Chase Sun Pharmaceutical Co., Ltd. Market Cap: CN¥11.99B Tianjin Chase Sun Pharmaceutical Co., Ltd, with a market cap of CN¥11.99 billion, reported first-quarter sales of CN¥1.39 billion and net income of CN¥60.33 million, showing slight growth from the previous year despite declining sales figures. The company's short-term assets significantly exceed its liabilities, and it holds more cash than debt, indicating a strong liquidity position. However, profit margins have decreased to 0.4% from 6.6% last year, raising concerns about profitability sustainability amid negative earnings growth over the past year and low return on equity at 0.3%. Recent board changes may influence strategic direction moving forward. Dive into the specifics of Tianjin Chase Sun PharmaceuticalLtd here with our thorough balance sheet health report. Assess Tianjin Chase Sun PharmaceuticalLtd's future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hunan Er-Kang Pharmaceutical Co., Ltd is engaged in the manufacturing and sale of APIs, finished drug products, and pharmaceutical excipients both in China and internationally, with a market cap of CN¥6.91 billion. Operations: Hunan Er-Kang Pharmaceutical Co., Ltd has not reported specific revenue segments. Market Cap: CN¥6.91B Hunan Er-Kang Pharmaceutical, with a market cap of CN¥6.91 billion, has shown mixed financial performance. Despite a decline in annual revenue from CN¥1.78 billion to CN¥1.14 billion and an increased net loss of CN¥373.37 million for 2024, the company reported improved first-quarter sales of CN¥353.55 million and net income of CN¥28.11 million in 2025 compared to the previous year. The company's short-term assets exceed both its long-term and short-term liabilities, indicating strong liquidity, yet its negative return on equity and high share price volatility highlight ongoing profitability challenges amid increased debt levels over time. Navigate through the intricacies of Hunan Er-Kang Pharmaceutical with our comprehensive balance sheet health report here. Review our historical performance report to gain insights into Hunan Er-Kang Pharmaceutical's track record. Navigate through the entire inventory of 1,001 Asian Penny Stocks here. Want To Explore Some Alternatives? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SZSE:002102 SZSE:300026 and SZSE:300267. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati
Yahoo
an hour ago
- Yahoo
Welfare U-turn raises questions over Labour's tax plans
Labour faces renewed speculation over its tax plans after concessions to the party's welfare rebels left a £4.8 billion hole in Rachel Reeves's spending plans. The concessions, including the last-minute shelving of plans to restrict eligibility for personal independence payments (Pip), were enough to head off the Government's first Commons defeat on Tuesday evening. But they also removed a key plank of Sir Keir Starmer's welfare reform agenda, delaying changes to Pip until after a review of the benefit not due to conclude until autumn 2026. With no clarity on when the changes will be enacted or what they might entail, the Chancellor now faces a fiscal headache as a forecast £4.8 billion in welfare savings have been whittled away to nothing. Economists at the Institute for Fiscal Studies (IFS) and Resolution Foundation think tanks warned that Tuesday's concessions meant Ms Reeves could now expect no 'net savings' by 2029/30 – a key year for meeting her fiscal targets. IFS deputy director Helen Miller said the move had effectively halved the Chancellor's 'margin of error' against her main fiscal rule, once again raising the possibility of tax rises in the autumn. On top of that, a stuttering economy and global instability could mean she has even less room for manoeuvre than expected. Ms Miller said: 'Since departmental spending plans are now effectively locked in, and the Government has already had to row back on planned cuts to pensioner benefits and working-age benefits, tax rises would look increasingly likely.' The Resolution Foundation's Ruth Curtice agreed that there would be no savings in 2029/30, but suggested changes to universal credit – almost the only part of the Government's proposals still standing – could save money in the longer term. On Wednesday morning, the Conservatives accused Labour of making billions in unfunded spending commitments, including both the U-turns on welfare and the partial reinstatement of winter fuel payments. In a letter to Ms Reeves, shadow chancellor Sir Mel Stride demanded to know where the money was coming from, asking: 'Will you raise tax or increase borrowing?' Ministers have repeatedly insisted that Labour will not raise taxes on 'working people', specifically income tax, national insurance or VAT. But Ms Reeves also remains committed to her 'iron clad' fiscal rules, which require day-to-day spending to be covered by revenues – not borrowing – in 2029/30. Meanwhile, Sir Keir himself will face a grilling from MPs on Wednesday as he attempts to repair relations with his backbenchers. The weekly session of Prime Minister's Questions comes just a day after 49 of his own MPs voted against his welfare reforms – the biggest rebellion of his premiership so far – while several backbenchers described the Government's handling of the issue as 'chaotic' and 'a shambles'.
